JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Danaher (NYSE:DHR) Stock

Key Points

• JPMorgan raised Danaher’s price target to $270 from $250 and maintained an “overweight” rating, implying roughly 14.8% upside from the prior close.
• Danaher reported adjusted quarterly EPS of $2.11, beating the $1.92 consensus estimate, while revenue increased 8.3% year over year to $6.55 billion. Management also raised its full-year 2026 adjusted EPS outlook to $8.57–$8.62.
• Analyst sentiment has broadly improved following the results, with Stifel, Baird and Goldman Sachs raising their targets; Danaher currently carries a “Moderate Buy” consensus rating and an average price target of $239.50.

Danaher (NYSE:DHR - Get Free Report) had its price target hoisted by investment analysts at JPMorgan Chase & Co. from $250.00 to $270.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the conglomerate's stock. JPMorgan Chase & Co.'s price target suggests a potential upside of 14.78% from the company's previous close.

Several other equities research analysts also recently issued reports on DHR. Wells Fargo & Company cut their target price on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 22nd. Wall Street Zen downgraded Danaher from a "buy" rating to a "hold" rating in a report on Sunday. Stifel Nicolaus boosted their price target on Danaher from $220.00 to $260.00 and gave the company a "buy" rating in a research note on Thursday. Robert W. Baird raised their target price on shares of Danaher from $246.00 to $254.00 and gave the company an "outperform" rating in a report on Thursday. Finally, Barclays reissued an "overweight" rating and set a $260.00 price target on shares of Danaher in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average target price of $239.50.

Danaher Stock Performance

Shares of Danaher stock opened at $235.23 on Thursday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80. The stock's fifty day simple moving average is $215.25 and its 200 day simple moving average is $196.84. The company has a market capitalization of $165.37 billion, a PE ratio of 41.80, a PEG ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.92 by $0.19. The company had revenue of $6.55 billion during the quarter, compared to analysts' expectations of $6.56 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business's quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.89 earnings per share. On average, research analysts predict that Danaher will post 8.53 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Main Street Group LTD acquired a new stake in Danaher in the first quarter worth $25,000. N.E.W. Advisory Services LLC bought a new position in shares of Danaher in the second quarter valued at approximately $25,000. Marquette Asset Management LLC lifted its holdings in shares of Danaher by 192.1% in the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 73 shares in the last quarter. Evolution Wealth Management Inc. boosted its holdings in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Finally, Field & Main Bank purchased a new position in Danaher during the second quarter worth about $29,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, well above the $1.92 consensus estimate. Revenue rose 8.3% year over year to $6.55 billion, essentially in line with expectations, while stronger Biotechnology profitability supported margin expansion. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, above the prior outlook and analyst expectations. Biotechnology orders grew at a mid-teens rate, suggesting improving customer demand and a potentially stronger recovery across key end markets. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Analysts became more constructive following the results. Stifel Nicolaus raised its price target from $220 to $260 and upgraded DHR to Buy, while Robert W. Baird lifted its target from $246 to $254 and assigned an Outperform rating. Goldman Sachs also increased its target to $275 from $250. Goldman Sachs Adjusts Price Target on Danaher
• Positive Sentiment: Management highlighted artificial-intelligence capabilities as a longer-term growth opportunity in drug discovery, while the Masimo acquisition helped offset weakness in respiratory diagnostic sales. Danaher says it has building blocks for AI drug discovery growth

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.